EGFR Activating Mutation Clinical Trials

8 recruitingLast updated: June 18, 2026

There are 8 actively recruiting egfr activating mutation clinical trials across 3 countries. Studies span Not Applicable, Phase 2, Phase 3. Top locations include Guangzhou, Guangdong, China, Beijing, Beijing Municipality, China, Boulogne, France. Updated daily from ClinicalTrials.gov.


EGFR Activating Mutation Trials at a Glance

8 actively recruiting trials for egfr activating mutation are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Not Applicable with 3 trials, with the heaviest enrollment activity in Guangzhou, Beijing, and Boulogne. Lead sponsors running egfr activating mutation studies include TYK Medicines, Inc, Intergroupe Francophone de Cancerologie Thoracique, and Guangzhou University of Traditional Chinese Medicine.

Browse egfr activating mutation trials by phase

Treatments under study

About EGFR Activating Mutation Clinical Trials

Looking for clinical trials for EGFR Activating Mutation? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new EGFR Activating Mutation trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about EGFR Activating Mutation clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC

EGFR Activating MutationLung Cancer Non-Small Cell Cancer (NSCLC)PD-1 Antibody
Nanfang Hospital, Southern Medical University32 enrolled1 locationNCT07637448
Recruiting
Not Applicable

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

Leptomeningeal MetastasisNSCLC (Advanced Non-small Cell Lung Cancer)EGFR Activating Mutation+1 more
Guangzhou University of Traditional Chinese Medicine42 enrolled1 locationNCT07348965
Recruiting
Not Applicable

CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease

Non-small Cell Lung CancerLeptomeningeal MetastasisEGFR Activating Mutation
British Columbia Cancer Agency10 enrolled1 locationNCT05257967
Recruiting
Phase 2

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

NSCLCBrain MetastasesEGFR Activating Mutation
TYK Medicines, Inc420 enrolled1 locationNCT05948813
Recruiting
Phase 2

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung CancerEGFR-TKI Resistant MutationEGFR Activating Mutation+1 more
Tianjin Medical University Cancer Institute and Hospital32 enrolled1 locationNCT06363734
Recruiting
Not Applicable

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

Non-small Cell Lung CancerEGFR Activating MutationEGFR DEL19+1 more
Intergroupe Francophone de Cancerologie Thoracique300 enrolled36 locationsNCT06053099
Recruiting
Phase 3

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

NSCLCEGFR Activating Mutation
TYK Medicines, Inc680 enrolled2 locationsNCT05382728
Recruiting
Phase 3

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Brain MetastasesRadiotherapyEGFR Activating Mutation
Sun Yat-sen University232 enrolled1 locationNCT05768490